252 related articles for article (PubMed ID: 37959313)
1. Mechanisms of Diabetic Nephropathy Not Mediated by Hyperglycemia.
Viggiano D
J Clin Med; 2023 Oct; 12(21):. PubMed ID: 37959313
[TBL] [Abstract][Full Text] [Related]
2. Renal pathology patterns in type II diabetes mellitus: relationship with retinopathy. The Collaborative Study Group.
Schwartz MM; Lewis EJ; Leonard-Martin T; Lewis JB; Batlle D
Nephrol Dial Transplant; 1998 Oct; 13(10):2547-52. PubMed ID: 9794557
[TBL] [Abstract][Full Text] [Related]
3. The efficacy and safety of SGLT2 inhibitors in patients with non-diabetic chronic kidney disease: a systematic review and meta-analysis.
Ma C; Li X; Li W; Li Y; Shui F; Zhu P
Int Urol Nephrol; 2023 Dec; 55(12):3167-3174. PubMed ID: 37046125
[TBL] [Abstract][Full Text] [Related]
4. The Molecular Effects of SGLT2i Empagliflozin on the Autophagy Pathway in Diabetes Mellitus Type 2 and Its Complications.
Saad R; Tadmor H; Ertracht O; Nakhoul N; Nakhoul F; Evgeny F; Atar S
J Diabetes Res; 2022; 2022():8337823. PubMed ID: 36313818
[TBL] [Abstract][Full Text] [Related]
5. Canagliflozin Prevents Intrarenal Angiotensinogen Augmentation and Mitigates Kidney Injury and Hypertension in Mouse Model of Type 2 Diabetes Mellitus.
Woods TC; Satou R; Miyata K; Katsurada A; Dugas CM; Klingenberg NC; Fonseca VA; Navar LG
Am J Nephrol; 2019; 49(4):331-342. PubMed ID: 30921791
[TBL] [Abstract][Full Text] [Related]
6. [AUTOPHAGY AND DIABETIC NEPHROPATHY].
Farber E; Hanut A; Tadmor H; Ruth A; Nakhoul F; Nakhoul N
Harefuah; 2021 Nov; 160(11):740-745. PubMed ID: 34817141
[TBL] [Abstract][Full Text] [Related]
7. A Strategic Investigation on Diabetic Nephropathy; Its Conceptual Model and clinical Manifestations: A Review.
Wal P; Tyagi S; Pal RS; Yadav A; Jaiswal R
Curr Diabetes Rev; 2023; 19(5):e260422204036. PubMed ID: 35993472
[TBL] [Abstract][Full Text] [Related]
8. Macrophages in mouse type 2 diabetic nephropathy: correlation with diabetic state and progressive renal injury.
Chow F; Ozols E; Nikolic-Paterson DJ; Atkins RC; Tesch GH
Kidney Int; 2004 Jan; 65(1):116-28. PubMed ID: 14675042
[TBL] [Abstract][Full Text] [Related]
9. Nodular glomerulosclerosis in a patient with cystic fibrosis, but not diabetes mellitus: A paediatric case.
Lalayiannis AD; Thompson C; Malcomson R; Milford DV
Respir Med Case Rep; 2016; 19():58-60. PubMed ID: 27489763
[TBL] [Abstract][Full Text] [Related]
10. Sodium-glucose cotransporter inhibitors and kidney fibrosis: review of the current evidence and related mechanisms.
Afsar B; Afsar RE
Pharmacol Rep; 2023 Feb; 75(1):44-68. PubMed ID: 36534320
[TBL] [Abstract][Full Text] [Related]
11. Cardiorenal Protections of SGLT2 Inhibitors in the Treatment of Type 2 Diabetes.
Nazari S; Mirkhani H
Curr Diabetes Rev; 2023; 19(8):e221222212126. PubMed ID: 36567296
[TBL] [Abstract][Full Text] [Related]
12. Prevention of progression of diabetic nephropathy by the SGLT2 inhibitor ipragliflozin in uninephrectomized type 2 diabetic mice.
Tahara A; Takasu T
Eur J Pharmacol; 2018 Jul; 830():68-75. PubMed ID: 29702076
[TBL] [Abstract][Full Text] [Related]
13. Sodium Glucose Cotransporter-2 Inhibitor Protects Against Diabetic Neuropathy and Nephropathy in Modestly Controlled Type 2 Diabetes: Follow-Up Study.
Ishibashi F; Kosaka A; Tavakoli M
Front Endocrinol (Lausanne); 2022; 13():864332. PubMed ID: 35784562
[TBL] [Abstract][Full Text] [Related]
14. Augmentation of kidney injury by basic fibroblast growth factor or platelet-derived growth factor does not induce progressive diabetic nephropathy in the Goto Kakizaki model of non-insulin-dependent diabetes.
Riley SG; Steadman R; Williams JD; Floege J; Phillips AO
J Lab Clin Med; 1999 Sep; 134(3):304-12. PubMed ID: 10482316
[TBL] [Abstract][Full Text] [Related]
15. Diffuse glomerular nodular lesions in diabetic pigs carrying a dominant-negative mutant hepatocyte nuclear factor 1-alpha, an inheritant diabetic gene in humans.
Hara S; Umeyama K; Yokoo T; Nagashima H; Nagata M
PLoS One; 2014; 9(3):e92219. PubMed ID: 24647409
[TBL] [Abstract][Full Text] [Related]
16. Report of the Committee on the classification and diagnostic criteria of diabetes mellitus.
Kuzuya T; Nakagawa S; Satoh J; Kanazawa Y; Iwamoto Y; Kobayashi M; Nanjo K; Sasaki A; Seino Y; Ito C; Shima K; Nonaka K; Kadowaki T;
Diabetes Res Clin Pract; 2002 Jan; 55(1):65-85. PubMed ID: 11755481
[TBL] [Abstract][Full Text] [Related]
17. Effects of the SGLT2 inhibitor ipragliflozin on various diabetic symptoms and progression of overt nephropathy in type 2 diabetic mice.
Tahara A; Takasu T
Naunyn Schmiedebergs Arch Pharmacol; 2018 Apr; 391(4):395-406. PubMed ID: 29374293
[TBL] [Abstract][Full Text] [Related]
18. Magnetic resonance diffusion tensor imaging for evaluation of histopathological changes in a rat model of diabetic nephropathy.
Hueper K; Hartung D; Gutberlet M; Gueler F; Sann H; Husen B; Wacker F; Reiche D
Invest Radiol; 2012 Jul; 47(7):430-7. PubMed ID: 22659594
[TBL] [Abstract][Full Text] [Related]
19. Diabetes and Cardiorenal Complications: A Clinical Review of Existing Therapies and Novel Combinations, Focusing on SGLT2 Inhibitors.
Kale A; Sharma A; Anders HJ; Gaikwad AB
Curr Diabetes Rev; 2023; 19(8):e160822207546. PubMed ID: 35975848
[TBL] [Abstract][Full Text] [Related]
20. Nodular glomerulosclerosis in cystic fibrosis mimics diabetic nephropathy.
Westall GP; Binder J; Kotsimbos T; Topliss D; Thomson N; Dowling J; Wilson JW
Nephron Clin Pract; 2004; 96(3):c70-5. PubMed ID: 15056988
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
